Botanical Monographs, Marketing Exclusivity Discussed By IoM Committee
This article was originally published in The Tan Sheet
Executive Summary
Botanical products should either conform to established monographs or be subjected to clinical trials that prove their safety and efficacy, health policy analyst Rowena Richter said at an IoM Committee meeting on U.S. consumers' use of complementary & alternative medicine held in Washington, D.C. June 30
You may also be interested in...
CAM Researcher Qualifications Review by IoM Cmte. Urged by Straus
The Institute of Medicine's Committee on the Use of Complementary & Alternative Medicine by the American Public should evaluate the different qualifications and knowledge sets CAM researchers bring to the study environment, NCCAM Director Stephen Straus, MD, said at the group's inaugural meeting in Washington, D.C. Feb. 27
Private CAM Research Incentives Advocated By White House Commission
The White House Commission on Complementary & Alternative Medicine Policy's final report will suggest the federal government provide incentives to stimulate private sector investment in CAM research
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC